Pfizer 2015 Annual Report Download - page 133

Download and view the complete annual report

Please find page 133 of the 2015 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 134

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134

Financial Summary
Pfizer Inc. and Subsidiary Companies
132
2015 Financial Report
Year Ended/As of December 31,(a)
(MILLIONS, EXCEPT PER COMMON SHARE DATA) 2015 2014 2013 2012 2011
Revenues(b) $ 48,851 $ 49,605 $ 51,584 $ 54,657 $61,035
Income from continuing operations(b) 6,975 9,119 11,410 9,021 7,860
Total assets(b), (c) 167,460 167,566 170,415 182,974 184,629
Long-term obligations(b), (c), (d) 73,064 74,357 73,801 77,758 79,287
Earnings per common share—basic
Income from continuing operations attributable to Pfizer Inc. common
shareholders $1.13 $1.43 $1.67 $1.21 $1.00
Discontinued operations—net of tax(e) —0.01 1.56 0.75 0.28
Net income attributable to Pfizer Inc. common shareholders $1.13 $1.44 $3.23 $1.96 $1.28
Earnings per common share—diluted
Income from continuing operations attributable to Pfizer Inc. common
shareholders $1.11 $1.41 $1.65 $1.20 $0.99
Discontinued operations—net of tax(e) —0.01 1.54 0.74 0.28
Net income attributable to Pfizer Inc. common shareholders $1.11 $1.42 $3.19 $1.94 $1.27
Cash dividends paid per common share $1.12 $1.04 $0.96 $0.88 $0.80
(a) Reflects the acquisition of Hospira on September 3, 2015 and the acquisition of King on January 31, 2011.
(b) All amounts reflect the June 24, 2013 disposition of Zoetis and its presentation as a discontinued operation in all periods prior to 2014 presented.
(c) All amounts reflect the retrospective adoption of a new accounting standard as of December 31, 2015 that requires all deferred tax assets and liabilities to be
classified as noncurrent in the balance sheet. See Notes to Consolidated Financial Statements––Note 1B. Adoption of New Accounting Standards.
(d) Defined as Long-term debt, Pension benefit obligations, net, Postretirement benefit obligations, net, Noncurrent deferred tax liabilities, Other taxes payable and
Other noncurrent liabilities.
(e) Includes (i) the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, (ii) the Nutrition business through November 30, 2012, the date of
disposal and (iii) the Capsugel business through August 1, 2011, the date of disposal.